Ubrogepant for the Treatment of Migraine-Reference-Cited by-同舟云学术

Ubrogepant for the Treatment of Migraine

Published:2019-12-05 Issue:23 Volume:381 Page:2230-2241
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Dodick David W.¹,Lipton Richard B.¹,Ailani Jessica¹,Lu Kaifeng¹,Finnegan Michelle¹,Trugman Joel M.¹,Szegedi Armin¹

Affiliation:

1. From the Mayo Clinic, Phoenix, AZ (D.W.D.); Albert Einstein College of Medicine and Montefiore Headache Center, Bronx, NY (R.B.L.); Georgetown University Hospital, Washington, DC (J.A.); and Allergan, Madison, NJ (K.L., M.F., J.M.T., A.S.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1813049

Cited by 267 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Invention of novel 3-aminopiperidin-2-ones as calcitonin gene-related peptide receptor antagonists;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome;Neurology;2024-09-24

3. Acupuncture for migraine: A systematic review and meta-regression of randomized controlled trials;Complementary Therapies in Medicine;2024-09

4. Evidence‐based review and frontiers of migraine therapy;Neurogastroenterology & Motility;2024-08-12

5. Documento de consenso de la Sociedad Española de Neurología (SEN), Sociedad Española de Medicina de Familia y Comunitaria (SEMFYC), Sociedad de Medicina de Atención Primaria (SEMERGEN) y Asociación Española de Migraña y Cefalea (AEMICE) sobre el tratamiento de la migraña;Medicina Clínica;2024-08